Compare DAKT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | GERN |
|---|---|---|
| Founded | 1968 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.5M | 1.1B |
| IPO Year | 1996 | N/A |
| Metric | DAKT | GERN |
|---|---|---|
| Price | $20.41 | $1.42 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 247.7K | ★ 14.8M |
| Earning Date | 03-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | $26.91 |
| Revenue Next Year | $9.16 | $43.75 |
| P/E Ratio | $26.71 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $13.05 | $1.04 |
| 52 Week High | $28.27 | $2.01 |
| Indicator | DAKT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 37.29 |
| Support Level | $18.99 | $1.24 |
| Resistance Level | $21.14 | $1.49 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 91.91 | 1.45 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.